Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech has received a European patent that is related to satraplatin, a novel, oral platinum compound.
Subscribe to our email newsletter
The patent covers certain uses of satraplatin related to the treatment of a cancer or tumor resistant or refractory to a taxane, including docetaxel (Taxotere) and paclitaxel (Taxol). The term of the patent extends up to 2025.
Bernd Seizinger, CEO of GPC Biotech, said: “With an active filing for satraplatin under review in Europe, we believe this patent will be of particular commercial importance, should satraplatin be approved for hormone-refractory prostate cancer patients whose prior chemotherapy has failed.”